Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Peijia Medical Raises $302 Million in Hong Kong IPO for Medical Devices

publication date: May 21, 2020

Peijia Medical of Suzhou completed a $302 million Hong Kong IPO for its medical device business. Peijia has developed a line of transcatheter heart valves and neurointerventional surgery devices for stroke. The company sold 25% of its expanded share base in the offering at a market capitalization of $1.2 billion. The shares available for public investors were 1,183 times oversubscribed, showing strong interest. The stock is trading about 8% higher above the offering price. More details....

Stock Symbol: (HK: 09996)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020